Company: INTS
Filing Date: 2025-04-25
Form Type: 8-K
Source: 0001628280-25-020057
Chunk: 1

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-04-25
Form: 8-K
Item: Item 1.01
Chunk 1
---
 Agreement”) with certain institutional investors. The Purchase Agreement contains customary representations and warranties, agreements of the Company and the investors and customary indemnification rights and obligations of the parties. Pursuant to the terms of the Purchase Agreement, the Company has agreed to certain restrictions on the issuance and sale of its Common Stock or Common Stock Equivalents (as defined in the Purchase Agreement) during the 30-day period following the closing of the Offering, subject to certain exceptions which includes the issuance of up to $5.0 million of shares of Common Stock and common stock purchase warrants to certain of our existing shareholders and/or any investor in this Offering, in proportion to their purchase in the Offering, in a registered offering pursuant to our existing Registration Statement on Form S-3, provided that such shares of Common Stock are issued and sold at a price per share equal to or greater than the offering price in the Offering. In addition, the Company has agreed not to effect or enter into an agreement to effect any issuance of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock involving a Variable Rate Transaction (as defined in the Purchase Agreement) until the 60-day anniversary of the closing date of the Offering, subject to certain exceptions.

The Shares, Warrants and Warrant Shares were offered by the Company pursuant to a Registration Statement on Form S-1 (File No. 333-286683) (the “ Registration Statement”), which was originally filed with the Securities and Exchange Commission (the “ Commission”) on April 22, 2025, as amended by Amendment No. 1 to the Form S-1 (including the prospectus forming a part of such Registration Statement), under the Securities Act of 1933, as amended (the “ Securities Act”), and was declared effective by the Commission on April 24, 2025.

A holder (together with its affiliates) may not exercise any portion of the Warrants to the extent that such holder would own more than 4.99% (or, at such holder’s option upon issuance, 9.99%) of the Company’s outstanding Common Stock immediately after exercise. However, upon at least 61 days’ prior notice from such holder to the Company, the holder may increase the amount of ownership of outstanding Common Stock after exercising the holder’s Warrants up to 9.99% of the number of the Company’s Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Warrants.